Novartis Japan

Novartis Japan company information, Employees & Contact Information

Explore related pages

Related company profiles:

ノバルティス ファーマは、スイス・バーゼル市に本拠を置くヘルスケアにおける世界的リーディングカンパニー、ノバルティスの医薬品部門の日本法人です。ノバルティス グループの世界的なネットワークと研究開発力を生かし、世界そして日本の人々の健康と豊かな生活を実現するために、革新的な医薬品を医療の現場にお届けしています。 コミュニティーガイドラインへのリンクはこちら https://www.novartis.com/jp-ja/linkedin-community-guideline

Company Details

Employees
87
Founded
-
Address
1丁目23番1号, 虎ノ門ヒルズ森タワー,japan
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
港区虎ノ門, 東京都
Looking for a particular Novartis Japan employee's phone or email?

Novartis Japan Questions

News

Novartis taps Argo again, inks potential $5.2B collaboration - BioWorld MedTech

Novartis taps Argo again, inks potential $5.2B collaboration BioWorld MedTech

Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases - PR Newswire

Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases PR Newswire

Novartis Drops up to $1B+ for Drug Discovery Deal With Matchpoint - BioSpace

Novartis Drops up to $1B+ for Drug Discovery Deal With Matchpoint BioSpace

Argo Biopharma Announces New Deal With Novartis For Novel Molecules For Cardiovascular Diseases - Nasdaq

Argo Biopharma Announces New Deal With Novartis For Novel Molecules For Cardiovascular Diseases Nasdaq

Novartis hands over $55M upfront to license preclinical hives prospect from Japan's Kyorin - Fierce Biotech

Novartis hands over $55M upfront to license preclinical hives prospect from Japan's Kyorin Fierce Biotech

JP Morgan 2025: Novartis streamlines its portfolio to drive future growth - Pharmaceutical Technology

JP Morgan 2025: Novartis streamlines its portfolio to drive future growth Pharmaceutical Technology

KYORIN and Novartis Forge Global License Agreement for KRP-M223 - TipRanks

KYORIN and Novartis Forge Global License Agreement for KRP-M223 TipRanks

Kyorin offers Novartis timely new weapon in urticaria - The Pharma Letter

Kyorin offers Novartis timely new weapon in urticaria The Pharma Letter

Novartis to mass produce next-generation cancer drugs in Japan - Nikkei Asia

Novartis to mass produce next-generation cancer drugs in Japan Nikkei Asia

Novartis Doubles Down on Argo Pact With Fresh $5.2B Commitment - BioSpace

Novartis Doubles Down on Argo Pact With Fresh $5.2B Commitment BioSpace

J.P. Morgan Healthcare Conference 2024 - Novartis

J.P. Morgan Healthcare Conference 2024 Novartis

Novartis's Japan Unit Faces Criminal Probe for Hypertension Drug Marketing - Science | AAAS

Novartis's Japan Unit Faces Criminal Probe for Hypertension Drug Marketing Science | AAAS

U.S. Supreme Court rebuffs Novartis, allows generic versions of MS drug - Reuters

U.S. Supreme Court rebuffs Novartis, allows generic versions of MS drug Reuters

Novartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia - Novartis

Novartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia Novartis

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) - Novartis

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Novartis

Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab - Novartis

Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab Novartis

Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death - Novartis

Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death Novartis

Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14 - Novartis

Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14 Novartis

Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA) - Novartis

Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA) Novartis

Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicines - Novartis

Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicines Novartis

Novartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease - Novartis

Novartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease Novartis

Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU - Novartis

Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU Novartis

Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatments - Novartis

Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatments Novartis

US Supreme Court rebuffs Novartis bid to revive MS drug Gilenya patent - Reuters

US Supreme Court rebuffs Novartis bid to revive MS drug Gilenya patent Reuters

Novartis receives EU approval for Tafinlar® and Mekinist®, first combination approved for patients with aggressive form of melanoma - Novartis

Novartis receives EU approval for Tafinlar® and Mekinist®, first combination approved for patients with aggressive form of melanoma Novartis

Novartis Looking for Constructive Ways To Bring Down Drug Costs in US - BioSpace

Novartis Looking for Constructive Ways To Bring Down Drug Costs in US BioSpace

BeiGene-Novartis gastric cancer drug succeeds in late-stage trial - Reuters

BeiGene-Novartis gastric cancer drug succeeds in late-stage trial Reuters

Novartis partners with Phase 4 Partners and institutional investors to help create Mereo BioPharma Group Ltd - Novartis

Novartis partners with Phase 4 Partners and institutional investors to help create Mereo BioPharma Group Ltd Novartis

Sun Pharma, Novartis co-opt the copay offer to promote knockoffs of pricey brands - Fierce Pharma

Sun Pharma, Novartis co-opt the copay offer to promote knockoffs of pricey brands Fierce Pharma

Novartis follows brand offloading trend, selling drugs in Japan to Sun - Fierce Pharma

Novartis follows brand offloading trend, selling drugs in Japan to Sun Fierce Pharma

Novartis, other investors try to delay sale of Proteus Digital Health - Fierce Healthcare

Novartis, other investors try to delay sale of Proteus Digital Health Fierce Healthcare

Judge in Japan lets Novartis off the hook in advertising scandal - Fierce Pharma

Judge in Japan lets Novartis off the hook in advertising scandal Fierce Pharma

Novartis, Amgen in dispute over migraine drug partnership - Reuters

Novartis, Amgen in dispute over migraine drug partnership Reuters

Zolgensma from Novartis receives Japan regulatory approval - Pharmaceutical Technology

Zolgensma from Novartis receives Japan regulatory approval Pharmaceutical Technology

Aspen alert! Novartis buys assets for $330m in Japan boost - BioProcess International

Aspen alert! Novartis buys assets for $330m in Japan boost BioProcess International

Patent case: Novartis Pharmaceuticals Corporation. v. Accord Healthcare, Inc., USA - Wolters Kluwer

Patent case: Novartis Pharmaceuticals Corporation. v. Accord Healthcare, Inc., USA Wolters Kluwer

Sun Pharma expands presence in Japan with $293 million deal for Novartis drugs - BioPharma Dive

Sun Pharma expands presence in Japan with $293 million deal for Novartis drugs BioPharma Dive

Propeller Health, Novartis Co-Package Asthma Medication in Europe for Prescription - HIT Consultant

Propeller Health, Novartis Co-Package Asthma Medication in Europe for Prescription HIT Consultant

Propeller's digital inhaler tech to be co-prescribed with Novartis' new asthma med - Fierce Biotech

Propeller's digital inhaler tech to be co-prescribed with Novartis' new asthma med Fierce Biotech

Novartis' Zolgensma faces EU, Japan delays after regulators raise 'manufacturing questions' - Fierce Pharma

Novartis' Zolgensma faces EU, Japan delays after regulators raise 'manufacturing questions' Fierce Pharma

Novartis pays China's Baiyu $70M upfront, with $1.1B chaser, for small molecule cancer candidate - Fierce Biotech

Novartis pays China's Baiyu $70M upfront, with $1.1B chaser, for small molecule cancer candidate Fierce Biotech

Novartis Japan unit under scrutiny - BBC

Novartis Japan unit under scrutiny BBC

After TIGIT divorce, Novartis returns tislelizumab to BeiGene as PD-1 gains first European nod - Fierce Pharma

After TIGIT divorce, Novartis returns tislelizumab to BeiGene as PD-1 gains first European nod Fierce Pharma

Swiss pharma firms plot different paths to blockbuster drugs - The Japan Times

Swiss pharma firms plot different paths to blockbuster drugs The Japan Times

Novartis: Reimagining medicine in Japan through innovation - The Japan Times

Novartis: Reimagining medicine in Japan through innovation The Japan Times

Being there: Amgen and Novartis roll out first ad campaign for migraine drug Aimovig - Fierce Pharma

Being there: Amgen and Novartis roll out first ad campaign for migraine drug Aimovig Fierce Pharma

Novartis Diovan scandal claims two more papers - Retraction Watch

Novartis Diovan scandal claims two more papers Retraction Watch

Novartis Europharm Ltd withdraws its applications for an extension of the indication for Exelon and Prometax (rivastigmine) - European Medicines Agency

Novartis Europharm Ltd withdraws its applications for an extension of the indication for Exelon and Prometax (rivastigmine) European Medicines Agency

Novartis co-leads Euthymics A round - - Global Corporate Venturing

Novartis co-leads Euthymics A round - Global Corporate Venturing

Korean brokerage firm to buy Novartis campus in Paris for $454 mn: report - The Korea Economic Daily Global Edition

Korean brokerage firm to buy Novartis campus in Paris for $454 mn: report The Korea Economic Daily Global Edition

Actavis UK Ltd v Novartis AG, Court of Appeal, 17 February 2010 - Wolters Kluwer

Actavis UK Ltd v Novartis AG, Court of Appeal, 17 February 2010 Wolters Kluwer

Japan files criminal complaint against pharma giant - worldfinance.com

Japan files criminal complaint against pharma giant worldfinance.com

Abusive patenting: Novartis & Co are using their “evergreening” p... - Public Eye

Abusive patenting: Novartis & Co are using their “evergreening” p... Public Eye

Novartis, Pfizer, Sanofi: How India's pharma GCCs transformed from back office to innovation powerhouse - Times of India

Novartis, Pfizer, Sanofi: How India's pharma GCCs transformed from back office to innovation powerhouse Times of India

Novartis research scrutinised in Japan - SWI swissinfo.ch

Novartis research scrutinised in Japan SWI swissinfo.ch

Sun Pharma acquires Novartis brands in Japan - BusinessLine

Sun Pharma acquires Novartis brands in Japan BusinessLine

NHS to lose out on new drugs, pharma firm Novartis warns - BBC

NHS to lose out on new drugs, pharma firm Novartis warns BBC

Novartis acquiring US firm Avidity Biosciences for $12 bn - Tuko News

Novartis acquiring US firm Avidity Biosciences for $12 bn Tuko News

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant